
Pleiotropic Multi-Drug Co-Assembled Nanocomposites Offer Protection Against Doxorubicin-Induced Cardiotoxicity
Introduction Doxorubicin (DOX), an anthracycline chemotherapy agent, remains the cornerstone in the treatment of hematologic malignancies and solid tumors, significantly contributing to improvements in the average 5-year cancer survival rate1. However, due …